Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $9.33 Average PT from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have been assigned a consensus rating of "Hold" from the five analysts that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.33.

A number of analysts have recently weighed in on ESPR shares. Needham & Company LLC reiterated a "buy" rating and set a $8.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, May 7th. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, May 8th. Finally, StockNews.com raised Esperion Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, May 9th.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bellevue Group AG grew its holdings in Esperion Therapeutics by 136.5% during the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company's stock worth $26,650,000 after acquiring an additional 5,739,800 shares during the period. Vanguard Group Inc. boosted its stake in shares of Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company's stock worth $23,655,000 after acquiring an additional 3,688,796 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new position in shares of Esperion Therapeutics in the 1st quarter valued at $107,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Esperion Therapeutics in the first quarter worth about $50,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $446,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR traded up $0.12 during trading on Wednesday, reaching $2.30. The stock had a trading volume of 6,964,358 shares, compared to its average volume of 7,017,525. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The firm's 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.12.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the previous year, the firm earned ($0.76) EPS. As a group, equities research analysts expect that Esperion Therapeutics will post -0.17 earnings per share for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.